Portal de investigación
Estudio en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de sonelokimab subcutáneo en participantes adultos con hidradenitis supurativa de moderada a grave.
Datos básicos
- Código:
- M1095-HS-302
- Protocolo:
- M1095-HS-302
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2024
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
A Case of Localised Immediate Hypersensitivity Reaction to Bimekizumab.
Lasheras-Perez, Miguel Antonio; (...); Ibanez-Echevarria, Ethel
Article. 10.1111/cod.14774. 2025
A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study
Puig, Lluis; (...); IMPULSE Investigators Grp
Article. 10.1159/000540019. 2024
Delusional parasitosis (Ekbom's syndrome).
Mansilla-Polo, M, Martin-Torregrosa, D, Botella-Estrada, R
Article. 10.1016/j.semerg.2024.102423. 2024
Dermatologic Consultations for Patients Hospitalized in Non-Dermatologic Wards: Results of a 384-Patient Cross-Sectional Study From a Tertiary Referral Hospital
Mansilla-Polo, M.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2024.10.030. 2024
Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review.
Mansilla-Polo M; (...); Botella-Estrada R
Letter. 10.1111/ddg.15502. 2024
Dermatological toxicities of talquetamab, a new bispecificantibody: case series and literature review
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Letter. 10.1111/ddg.15502_g. 2024
Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study
Duc Binh Phan; (...); Yiu, Zenas Zee Ngai
Meeting Abstract. 2024
Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study.
Phan, Duc Binh; (...); Yiu, Zenas Z N
Article. 10.1093/bjd/ljae454. 2024
Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain
Magdaleno-Tapial, Jorge; (...); Martorell-Calatayud, Antonio
Article. 10.1155/2024/5528484. 2024
Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice.
Butrón-Bris B; (...); de la Fuente H
Article. 10.1111/exd.15152. 2024
Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1016/j.abd.2024.04.004. 2024
Histological deep margins in cutaneous squamous cell carcinoma of the scalp and risk of recurrence.
Verdaguer-Faja, Julia; (...); Jaka, Ane
Article. 10.1111/jdv.20250. 2024
Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma
Gutzmer, Ralf; (...); Hauschild, Axel
Article. 10.1186/s12885-024-13101-z. 2024
Nodular hidradenoma: Case report and brief literature review.
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Article. 10.1016/j.patol.2025.100801. 2025
Oral Ruxolitinib could Increase the Aggressiveness of Cutaneous Squamous Cell Carcinomas: A 6-Patient Series
Lasheras-Perez, M. A.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2023.07.035. 2025
Paraoxonase I Activity and Its Relationship with Nutrition in Amyotrophic Lateral Sclerosis.
Proaño B; (...); de la Rubia Ortí JE
Article. 10.3390/antiox13081021. 2024
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.
Martorell A; (...); Magdaleno-Tapial J
Article. 10.1016/j.ad.2024.10.042. 2024
Recalcitrant Hailey-Hailey Disease With Satisfactory Response to Apremilast
Mansilla-Polo, M.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2024.10.025. 2024
Ruxolitinib for foreign body reaction to silicone in a patient with chronic graft-versus-host disease.
Palacios-Diaz, Rodolfo David; (...); Botella-Estrada, Rafael
Letter. 10.1111/ijd.17365. 2024
Ruxolitinib oral puede aumentar la agresividad de los carcinomas escamosos cutáneos: serie de 6 pacientes.
Lasheras-Perez MA; (...); Botella-Estrada R
Article. 10.1016/j.ad.2024.10.003. 2025
Safety of biosimilars compared with originator adalimumab for psoriasis: a multinational cohort study
Phan, Duc Binh; (...); Yiu, Zenas
Meeting Abstract. 10.1093/bjd/ljae360.068. 2024
Sarcoidosis cutánea tras inyecciones de plasma rico en plaquetas y maquillaje permanente de cejas.
Martín-Torregrosa D; (...); Botella-Estrada R
Article. 10.1016/j.ad.2024.10.043. 2024
Skin cancer risk after hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1111/ijd.17371. 2024
Slowed-down temporal vein refilling as diagnostic pearl in frontal fibrosing alopecia.
Mansilla-Polo, Miguel, Martin-Torregrosa, Daniel, Torres-Navarro, Ignacio
Article. 10.1016/j.jaad.2024.06.062. 2024
Study of Microsatellite Instability by Immunohistochemistry in a Cohort of Patients With Melanoma
Diaz, Rodolfo David Palacios; (...); Estrada, Rafael Botella
Article. 10.1111/cup.14758. 2025
Successful Treatment of Mogamulizumab-Associated Rash With Upadacitinib: Evidence From 2 Cases.
Martin-Torregrosa, Daniel; (...); Botella-Estrada, Rafael
Article. 10.1001/jamadermatol.2024.4582. 2024
Successful Treatment of Stimulator of Interferon Genes-Associated Vasculopathy of Infantile Onset SAVI Syndrome With Anifrolumab.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1001/jamadermatol.2024.2160. 2024
Treatment of palmoplantar psoriasis with oral roflumilast: a case series.
Lasheras-Perez, Miguel Antonio; (...); Botella-Estrada, Rafael
Article. 10.1093/ced/llae229. 2024
Use of an electrospun bioveil is safe and does not decrease skin graft take on burn wounds: A randomised, controlled clinical trial.
Perez-Del-Caz, Maria Dolores; (...); Perez-Plaza, Aranzazu
Article. 10.1016/j.burns.2025.107427. 2025